Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Parasternal Nerve Block in Cardiac Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01826851
Recruitment Status : Completed
First Posted : April 9, 2013
Results First Posted : August 1, 2018
Last Update Posted : August 1, 2018
Sponsor:
Information provided by (Responsible Party):
Peter A Knight, University of Rochester

Brief Summary:
Exparel is a new local analgesic (numbing medication) that is intended to be longer acting than currently available local analgesics. The purpose of this study is to determine whether use of Exparel to numb the nerves along the breastbone after open heart surgery, will decrease pain and pain medication use after surgery.

Condition or disease Intervention/treatment Phase
Coronary Artery Disease Pain, Postoperative Drug: Exparel Drug: Placebo Phase 2

Detailed Description:

This is a Phase 2, single-institution, randomized, double-blind, parallel-group, placebo-controlled trial of patients undergoing a median sternotomy for primary cardiopulmonary bypass grafting (CABG) surgery.

78 subjects (39 per treatment arm) will be randomized in a 1:1 ratio to receive a single-dose, parasternal nerve block with either 266 mg Exparel or placebo (0.9% normal saline solution). The nerve blocks will be performed under direct visualization at the end of surgery, just prior to sternal closure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 79 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Parasternal Intercostal Nerve Block in Post-Cardiac Surgery Patients: A Randomized, Controlled Trial of Extended-release Liposomal Bupivacaine (Exparel) Versus Placebo
Study Start Date : March 2013
Actual Primary Completion Date : June 2017
Actual Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

Drug Information available for: Bupivacaine

Arm Intervention/treatment
Experimental: Exparel
266 mg Exparel, single-dose injection.
Drug: Exparel

Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.

Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU.

Other Names:
  • SKY0402
  • Bupivacaine liposome extended-release injectable suspension

Placebo Comparator: Placebo
0.9% Normal saline, single-dose injection.
Drug: Placebo

Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.

Post-surgical pain management will be the same as for the Exparel group.

Other Name: Preservative-free normal saline




Primary Outcome Measures :
  1. Median Cumulative Morphine Equivalent [ Time Frame: Outcome was measured at 1,2,4,8,12,24,36,48,60, and 72 hours post intercostal nerve block. ]
    The cumulative opioid requirement is reported as morphine equivalent. The total amount of narcotics required by the subjects in the Exparel group and placebo group were measured at 1,2,4,8,12,24,36,48,60, and 72 hours post-injection of Exparel or 0.9% normal saline. The amounts were analyzed and are reported as morphine equivalents.

  2. Median Pain Levels [ Time Frame: Outcome was measured at 1,2,4,8,12,24,36,48,60, and 72 hours post intercostal nerve block. ]
    The pain scores of the subjects in the Exparel group and placebo group were measured at 1,2,4,8,12,24,36,48,60, and 72 hours post-injection of Exparel or 0.9% normal saline. The pain scores were reported on a scale of 0 - 10. 0 being no pain. 10 being the worst pain.


Secondary Outcome Measures :
  1. Time to Extubation (Hours) [ Time Frame: 77 hours ]
    Time to remove endotracheal tube following surgery.

  2. ICU Length of Stay (Hours) [ Time Frame: 135 hours ]
    Duration of time spent in the intensive care unit postoperatively.

  3. Time to First Bowel Movement (Days) [ Time Frame: 35 days ]
    Time to first bowel movement following surgery.

  4. Hospital Length of Stay (Days) [ Time Frame: 25 days ]
    Duration of time spent in the hospital following surgery.

  5. Time to Return to Work or Daily Activities [ Time Frame: 36 days ]
    Time to return to work or daily activities following surgery will be assessed at postoperative clinic follow up or during a follow up telephone interview.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ≥ 18 years old
  • non-emergent coronary artery bypass grafting surgery (on and off pump)
  • median sternotomy

Exclusion Criteria:

  • Concomitant cardiac procedures (e.g. aortic valve repair/replacement, mitral valve repair/replacement, aortic root replacements).
  • Redo sternotomy.
  • < 50 kg (Exparel® is currently only approved in patients > 50 kg).
  • Pregnant or nursing
  • History of alcohol, narcotic or illicit drug abuse
  • Participation in another study evaluating investigational medications within the past 30 days
  • Taking narcotic analgesics within 3 days pre-operatively or perioperative stress-dose steroids.
  • Chronic non-cardiac pain (e.g. lower back pain, fibromyalgia) requiring narcotic analgesics.
  • Pre-operative mild liver insufficiency as defined by liver function tests [(i.e. alanine aminotransferase (ALT), aspartate aminotransferase (AST)] ≥ 1.5 times the upper limit of normal (ULN: ALT: 0-35 U/L, AST: 0-35 U/L, Alk Phos 35-105 U/L, Total bilirubin: 0-1.2 mg/dL)
  • Pre-operative mild renal insufficiency (Cr ≥ 1.5 mg/dL)
  • Allergy to amide-type anesthetics
  • Recurrent ventricular arrhythmias, low cardiac output requiring inotrope and/or intra-aortic balloon pump support, left ventricular ejection fraction < 30% at time of pre-operative screening/evaluation.
  • Unable to provide informed consent or unable to understand how to use pain rating scales.
  • Inability to understand or operate the patient-controlled analgesia (PCA) machine.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01826851


Locations
Layout table for location information
United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 14642
Sponsors and Collaborators
Peter A Knight
Investigators
Layout table for investigator information
Principal Investigator: Peter A Knight, MD University of Rochester
  Study Documents (Full-Text)

Documents provided by Peter A Knight, University of Rochester:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Peter A Knight, Professor, Cardiac Surgery, University of Rochester
ClinicalTrials.gov Identifier: NCT01826851    
Other Study ID Numbers: RSRB 00044181
First Posted: April 9, 2013    Key Record Dates
Results First Posted: August 1, 2018
Last Update Posted: August 1, 2018
Last Verified: July 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Peter A Knight, University of Rochester:
Pain management
Anesthetic, local
Nerve blockade
Coronary Artery Bypass Surgery
Analgesics, opioid
Postoperative complications
Bupivacaine
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Pain, Postoperative
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Postoperative Complications
Pathologic Processes
Pain
Neurologic Manifestations
Bupivacaine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents